Prothena | PRTA - Ebitda


Prothena reported $25.98M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 80.26M 20.05M Mar/2026
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Exelixis USD 258.29M 15.43M Mar/2026
Immunic USD -22.78M 753K Jun/2024
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
MacroGenics USD -30.2M 52.15M Mar/2026
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Prothena USD 25.98M 65.51M Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xoma USD 2.52M 7.98M Jun/2024